News

Kevin Darrington appointed as Tops Markets COO

BY Alaric DeArment

WILLIAMSVILLE, N.Y. Tops Markets has appointed a new COO, the supermarket chain announced Wednesday.

The company named Kevin Darrington COO. Darrington began working for Tops in 2008 as CFO, a position he will retain. In the COO position, he will be responsible for all merchandising and marketing functions, as well as direction, control and coordination of finance and information technology for the chain.

“Over the last two years, Kevin has been an invaluable member of Tops’ executive team,” president and CEO Frank Curci said in a statement. “He played a vital role in transitioning our company back to local management and, most recently, was instrumental in facilitating the purchase of a majority of Penn Traffic’s assets.”

Darrington was SVP and chief accounting officer of Pathmark Stores prior to working for Tops.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

FDA to have Genzyme plant inspected, reviewed

BY Alaric DeArment

CAMBRIDGE, Mass. Genzyme Corp. will have to submit to inspections of one of its plants by the Food and Drug Administration and pay fees to the agency under a consent decree, the biotechnology company said Wednesday.

The FDA will likely hire a third party to inspect and review Genzyme’s plant in the Boston neighborhood of Allston for an extended period of time to ensure its compliance with accepted manufacturing standards. Genzyme will also have to pay the FDA for the inspections, and may have to pay other fees as well.

The action comes as a result of an incident in June 2009, when the company detected a virus that inhibits cell growth in one of the containers it uses to manufacture drugs; the virus, vesivirus 2117, is not known to cause human infection. The company said the virus was the cause of declines in productivity at two of its plants, including Allston, in 2008, and was likely introduced via a nutrient used in the manufacturing process.

In November 2009, the company found particulate matter in supplies of drugs from the Allston plant, particularly the Gaucher disease drug Cerezyme (imiglucerase), the Fabry disease drug Fabrazyme (agalsidase beta), the Pompe disease drug Myozyme (alglucosidase alfa), the mucopolysaccharidosis treatment Aldurazyme (laronidase) and the thyroid disease drug Thyrogen (thyrotropin alfa).

The drug maker said it expected shipments of the Cerezyme, Fabrazyme and Myozyme, which are manufactured at the Allston plant, to continue uninterrupted.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

SVP product development and clinical operations

BY Alaric DeArment

HAYWARD, Calif. A company that develops drugs for inflammatory diseases has made a new executive appointment.

Anthera Pharmaceuticals announced that it hired Georgina Kilfoil for the newly-created position of SVP product development and clinical operations. Prior to working for Anthera, Kilfoil was a consultant at InClin and VP alliances and project management at Peninsula Pharmaceuticals.

“Georgina brings over 18 years of project management and clinical research expertise, making her a valuable and welcome addition to our senior management team,” Anthera president and CEO Paul Truex said in a statement.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?